Business
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
Volker Knappertz, MD, as Executive Vice President, Research and Development, to lead the consolidated R&D function and to further enhance and advance the
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\nVolker Knappertz, MD, as Executive Vice President, Research and Development, to lead the consolidated R&D function and to further enhance and advance the Aurinia pipeline\n\nScott Habig, as Chief Commercial Officer, to lead and enhance Aurinia’s commercial capabilities, replacing Max Colao, who led the formation of the commercial organization and the launch of Aurinia’s first FDA-approved product LUPKYNIS®\n\nDeDe Sheel, as Vice President of Investor Relations (IR), to manage all aspects of investor relations programs to support company growth\n\n VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced the appointment of three seasoned leaders to the Aurinia executive team. Volker Knappertz, MD, will join Aurinia as Executive Vice President (EVP), Research and Development to lead the consolidated Research and Development function. Additionally, Scott Habig has been named Aurinia’s new Chief Commercial Officer and will lead efforts to ensure further commercial success for LUPKYINIS®, Aurinia’s first FDA approved product, as well as future products. DeDe Sheel has been hired as Vice President (VP), Investor Relations, where she will manage the Company’s relationships with investors and analysts, and assist them in understanding the Company’s business model, long-term strategy, governance, and financial performance.\n\nMax Colao, who led the formation of Aurinia’s commercial organization and the launch of LUPKYNIS in 2021, is leaving the company to tend to personal matters. Neil Solomons, MD, Chief Medical Officer and Robert B. Huizinga, PhD, RN, CNeph(C), EVP, Research will remain in their current roles and continue as members of the executive committee.\n\n“These new hires bring a wealth of critical experience to Aurinia, and I am thrilled to add them to our team as we continue to execute on our strategy of building a fully integrated biopharmaceutical company,” said Peter Greenleaf, President, and Chief Executive Officer of Aurinia. “Volker has a strong track record of advancing biotechnology and medical innovation and is recognized for his leadership in creating diverse, high performing teams, and fostering creativity in R&D...